Targeting Neuropilin-1 with EG00229 Attenuates Pulmonary Arterial Hypertension in a Murine Sugen/Hypoxia Model

Pulmonary arterial hypertension (PAH) is a progressive vasculopathy driven by pulmonary vascular remodeling that leads to right ventricular failure and premature death. Despite improvements with therapies targeting the three canonical vasoactive pathways (nitric oxide, endothelin, and prostacyclin)─including endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, soluble guanylyl cyclase stimulators, and prostacyclin analogues─most patients do not achieve disease remission. This highlights the critical need for disease-modifying approaches that directly target and reverse pathological vascular remodeling. Recent advances, including the approval of the activin-signaling inhibitor sotatercept, suggest the feasibility of strategies that target novel antiremodeling pathways; however, PAH remains incurable for the vast majority. Neuropilin-1 (NRP1) is a multifunctional coreceptor expressed by endothelial cells (ECs) and pulmonary artery smooth muscle cells (PASMCs). The receptor orchestrates intracellular signaling by binding multiple ligands implicated in PAH pathobiology, including vascular endothelial growth factor (VEGF)-A, transforming growth factor (TGF)-β family members and platelet-derived growth factors (PDGFs), and modulates endothelial junctional stability, permeability and smooth muscle cell migration Here, we show that NRP1 is overexpressed in pulmonary artery smooth muscle cells from patients with PAH and that pharmacological inhibition of NRP1 with the novel small-molecule antagonist EG00229 attenuates hemodynamic and structural features of the disease in the gold-standard Sugen 5416/hypoxia (SuHx) mouse model of PAH. EG00229 reduced right-ventricular systolic pressure, right ventricular hypertrophy, and pulmonary arterial muscularization without affecting systemic blood pressure or body weight, supporting on-target pulmonary selectivity. These findings identify NRP1 as a tractable therapeutic target with potential to modulate vascular remodeling in PAH.

Authors

Institutions

Publication Details

Journal
ACS Pharmacology & Translational Science
Published
2026-11-19
DOI
https://doi.org/10.1021/acsptsci.6c00226
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting Neuropilin-1 with EG00229 Attenuates Pulmonary Arterial Hypertension in a Murine Sugen/Hypoxia Model

Reshma S. Baliga, David L. Selwood, Adrian J. Hobbs, Paul Frankel et al.
ACS Pharmacology & Translational Science
Pulmonary Hypertension Research and Treatments
article

Targeting Neuropilin-1 with EG00229 Attenuates Pulmonary Arterial Hypertension in a Murine Sugen/Hypoxia Model

Reshma S. Baliga, David L. Selwood, Adrian J. Hobbs, Paul Frankel, Lucie H. Clapp, Kersti Karu, Jigisha A. Patel, James M. Berg
article en

Abstract

Pulmonary arterial hypertension (PAH) is a progressive vasculopathy driven by pulmonary vascular remodeling that leads to right ventricular failure and premature death. Despite improvements with therapies targeting the three canonical vasoactive pathways (nitric oxide, endothelin, and prostacyclin)─including endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, soluble guanylyl cyclase stimulators, and prostacyclin analogues─most patients do not achieve disease remission. This highlights the critical need for disease-modifying approaches that directly target and reverse pathological vascular remodeling. Recent advances, including the approval of the activin-signaling inhibitor sotatercept, suggest the feasibility of strategies that target novel antiremodeling pathways; however, PAH remains incurable for the vast majority. Neuropilin-1 (NRP1) is a multifunctional coreceptor expressed by endothelial cells (ECs) and pulmonary artery smooth muscle cells (PASMCs). The receptor orchestrates intracellular signaling by binding multiple ligands implicated in PAH pathobiology, including vascular endothelial growth factor (VEGF)-A, transforming growth factor (TGF)-β family members and platelet-derived growth factors (PDGFs), and modulates endothelial junctional stability, permeability and smooth muscle cell migration Here, we show that NRP1 is overexpressed in pulmonary artery smooth muscle cells from patients with PAH and that pharmacological inhibition of NRP1 with the novel small-molecule antagonist EG00229 attenuates hemodynamic and structural features of the disease in the gold-standard Sugen 5416/hypoxia (SuHx) mouse model of PAH. EG00229 reduced right-ventricular systolic pressure, right ventricular hypertrophy, and pulmonary arterial muscularization without affecting systemic blood pressure or body weight, supporting on-target pulmonary selectivity. These findings identify NRP1 as a tractable therapeutic target with potential to modulate vascular remodeling in PAH.

ACS Pharmacology & Translational Science
Queen Mary University of London (GB), University College London (GB)
Pulmonary Hypertension Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon